Alteon halts hypertension trial

Alteon of Parsippany, New Jersey, has halted its Phase IIb trial of alagebrium after an independent review board concluded it did not demonstrate sufficient efficacy against uncontrolled systolic hypertension. The company also announced that it had submitted preclinical toxicity data on alagebrium to two divisions of the FDA supporting its view that liver alterations previously observed in rats, which led to a voluntary suspension of enrolling new patients into its clinical trials, were related to the male rat metabolism and not to genotoxic pathways.

- read this press release for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.